Currently out of the existing stock ratings of Jeffrey La Rosa, 9 are a BUY (100%).

Jeffrey La Rosa

Work Performance Price Targets & Ratings Chart

Analyst Jeffrey La Rosa, currently employed at LEERINK, carries an average stock price target met ratio of 33.33% that have a potential upside of 4.24% achieved within 83 days.

Jeffrey La Rosa’s has documented 18 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PYXS, Pyxis Oncology at 02-Jul-2026.

Wall Street Analyst Jeffrey La Rosa

Analyst best performing recommendations are on ABBV (ABBVIE).
The best stock recommendation documented was for ABBV (ABBVIE) at 2/3/2025. The price target of $210 was fulfilled within 220 days with a profit of $28.83 (15.91%) receiving and performance score of 0.72.

Average potential price target upside

ABBV AbbVie JANX Janux Therapeutics PYXS Pyxis Oncology

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 19-Feb-2026

$325

$40.2 (14.12%)

$300

Buy Since 04-Feb-2020

$288

$3.2 (1.12%)

$288

15 days ago
(09-Oct-2026)

45/45 (100%)

$11.53 (4.17%)

407

Hold Since 06-Jan-2026

$275

$-9.8 (-3.44%)

$260

15 days ago
(09-Oct-2026)

5/5 (100%)

$-1.47 (-0.53%)

76

Buy Since 16-Oct-2020

$300

$15.2 (5.34%)

$280

16 days ago
(08-Oct-2026)

20/21 (95.24%)

$27.58 (10.12%)

441

Buy Since 15-Nov-2023

$290

$5.2 (1.83%)

$285

16 days ago
(08-Oct-2026)

31/32 (96.88%)

$17.58 (6.45%)

251

Show more analysts

Please expand the browser size to see the chart

Which stock is Jeffrey La Rosa most bullish on?

Potential upside of $28.34 has been obtained for JANX (JANUX THERAPEUTICS)

Which stock is Jeffrey La Rosa most reserved on?

Potential downside of $5.32 has been obtained for PYXS (PYXIS ONCOLOGY)

What Year was the first public recommendation made by Jeffrey La Rosa?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?